Claims
- 1. An isolated nucleic acid sequence which codes for the amino acid sequence shown in FIG. 2.
- 2. The isolated nucleic acid sequence of claim 1 which has the nucleotide sequence as shown from base 139 to base 4353 in FIG. 6.
- 3. The isolated nucleic acid sequence of claim 2 which has the entire nucleic acid sequence shown in FIG. 6.
- 4. An isolated ribonucleic acid sequence transcribed from the nucleic acid sequence of claim 2.
- 5. The ribonucleic acid of claim 4 which has a nucleotide sequence about 8 kilobases long.
- 6. An isolated polypeptide having the amino acid sequence shown in FIG. 2.
- 7. The isolated polypeptide of claim 6 which has a molecular weight of about 160 kDa.
- 8. The isolated polypeptide of claim 6 which consists of 1404 amino acids.
- 9. An isolated polypeptide which is encoded by the nucleic acid of claim 2.
- 10. An isolated antibody which binds to protein products of P2P cDNA.
- 11. The isolated antibody of claim 10 which binds to the carboxy-terminal half of the polypeptide shown in FIG. 2.
- 12. The isolated antibody of claim 11 which is designated C130.
- 13. An isolated antisense oligonucleotide which binds to a domain of the open reading frame of claim 2.
- 14. The isolated antisense oligonucleotide of claim 13 which has the sequence 5′ CAGCAGGAGCTGTGTT 3′.
- 15. A method for repressing the proliferative potential of a cell selected from the group of normal, abnormal, and cancer cells comprising contacting DNA from the cell with an antisense oligonucleotide which binds to a domain of the open reading frame of P2P cDNA.
- 16. The method of claim 15 wherein the antisense oligonucleotide has the sequence 5′ CAGCAGGAGCTGTGTT 3′.
Parent Case Info
[0001] This application is a continuation of pending provisional application 60/027,568, filed Sep. 27, 1995.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60027568 |
Sep 1996 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08801308 |
Feb 1997 |
US |
Child |
09811045 |
Mar 2001 |
US |